View Older Stories View More Recent Stories
-
Starboard Releases 13F, Shows Two New Stakes
-
U.S. Government's Announcement On Pharma Sector Probe And Tariffs Unlikely For A Few Weeks, Sources Say - Reuters
-
Cantor Fitzgerald Reiterates Neutral Rating on Pfizer (PFE)
-
Pfizer, Astellas report positive trial results for bladder cancer combo
-
FDA accepts Arvinas drug application for advanced breast cancer treatment
-
Pfizer (PFE) PT Raised to $33 at Morgan Stanley
-
Pfizer (PFE) Tops Q2 EPS by 21c, Beats on Revenue; Offers FY25 EPS Guidance
-
Pfizer Inc earnings preview Q2: set for flat qtr, watch for guidance upgrade
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
FDA: Discontinuing manufacturing of Pfizer's Glucatrol XL, tablet, extended release, 10 mg tablets; bottle of 500
-
Pfizer completes $1.25 billion licensing deal with 3SBio for cancer drug
-
Bristol Myers Squibb and Pfizer launch direct-to-patient Eliquis program
-
ViiV Healthcare expands licensing deal for HIV treatment access in 133 countries
-
XTANDI plus leuprolide extends survival in prostate cancer patients
-
EnergyX agrees to acquire 35,000-acre Arkansas lithium deposit for $40M
-
US House committee subpoenas former Pfizer (PFE) executive in probe of alleged Covid vaccine delay - CNN
-
Pfizer (PFE) Announces Positive Topline Phase 3 Results for HYMPAVZI in Hemophilia A or B with Inhibitors
-
Pfizer (PFE) Declares $0.43 Quarterly Dividend; 7.1% Yield
-
Opus Genetics (IRD) CFO departs; Amy Rabourn named interim principal financial officer
-
FDA: manufacture of Pfizer's (PFE) docetaxel, injection, 160 mg/16 ml (10 mg/ml) multiple dose onco-tain glass fliptop vial novaplus discontinued - website
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
Trump Administration Said To Consider Crackdown On Pharma Ads - Bloomberg
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
BMO Capital: ACIP Cuts a Broad Negative To the Vaccine Space
-
Cantor Fitzgerald Reiterates Neutral Rating on Pfizer (PFE)
-
Kennedy Removing All Members Of CDC Panel Advising On Vaccines
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
Pfizer (PFE) CEO: The Trump Administration Has Had a Series of Meetings With Companies on Most Favored Nation Pricing
-
Arvinas (ARVN) stock rises on FDA submission with Pfizer (PFE)
-
Arvinas Inc. (ARVN) Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board of Directors for Breach of Fiduciary Duties (PFE)
-
Jefferies Reiterates Buy Rating on Pfizer (PFE)
-
Citi Reiterates Neutral Rating on Pfizer (PFE)
-
Pfizer's (PFE) BRAFTOVI Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
-
Astrellas and Pfizer's (PFE) announces results from Phase 3 study on XTANDI
-
Pfizer (PFE) Prostate Cancer Drug Fails To Get FDA Panel Backing - Bloomberg
-
Guggenheim Reiterates Buy Rating on Pfizer (PFE)
-
Pfizer (PFE) PT Raised to $33 at Jefferies
-
SK Bioscience wins patent lawsuit against Pfizer (PFE)
-
FDA Mandates Trials For Covid Boosters For Healthy Kids, Adults - NEJM
-
Bernstein Reiterates Market Perform Rating on Pfizer (PFE) Following SMMT Deal
-
Cantor Fitzgerald Reiterates Neutral Rating on Pfizer (PFE)
-
Pfizer (PFE) Enters into Exclusive Licensing Agreement with 3SBio
-
HHS plans to stop recommending Covid shots for children and pregnant women - WSJ
-
RFK Jr.'s HHS to Stop Recommending Routine Covid Shots for Kids, Pregnant Women -- WSJ
-
UnitedHealth stock falls on criminal probe, Mizuho sees risk of Dow removal
-
Trump says drug prices to be cut by 59%
-
Trump: Dr. Casey Means Nominated For Surgeon General
-
Trump to pitch sweeping Medicare drug price plan - Politico
